Search

Your search keyword '"Donnelly, J Peter"' showing total 496 results
Start Over Author "Donnelly, J Peter"
496 results on '"Donnelly, J Peter"'

51. The Fungal PCR Initiative’s evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: towards a standard for a diagnostics assay

Author

Gits-Muselli, Maud, White, P. Lewis, Mengoli, Carlo, Chen, Sharon, Crowley, Brendan, Dingemans, Gijs, Fréalle, Emilie, Gorton, Rebecca, Guiver, Malcom, Hagen, Ferry, Halliday, Catriona, Johnson, Gemma, Lagrou, Katrien, Lengerova, Martina, Melchers, Willem Jg, Novak-Frazer, Lily, Rautemaa-Richardson, Riina, Scherer, Emeline, Steinmann, Joerg, Cruciani, Mario, Barnes, Rosemary, Donnelly, J. Peter, Loeffler, Juergen, Bretagne, Stéphane, Alanio, Alexandre, Mycologie moléculaire - Molecular Mycology, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), International University of Health and Welfare Hospital (IUHW Hospital), Universita degli Studi di Padova, The University of Sydney, St James's University Hospital, Leeds Teaching Hospitals NHS Trust, Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Centre d’Infection et d’Immunité de Lille - INSERM U 1019 - UMR 9017 - UMR 8204 (CIIL), Centre National de la Recherche Scientifique (CNRS)-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Manchester University NHS Foundation Trust (MFT), University Medical Center [Utrecht], University Hospitals Leuven [Leuven], Mendel University in Brno (MENDELU), Radboud University Medical Center [Nijmegen], Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), University of Duisburg-Essen, Ospedale Fracastoro San Bonifacio [Verona], Cardiff University, Radboud university [Nijmegen], Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), We would like to thank Aude Sturny-Leclère, Marion Benazra, and Dirk Schmid for technical assistance and Dr Samia Hamane for her aid in managing the routine diagnosis of PCP. We also thank Pr Anne Bergeron who is in charge of the broncho-alveolar lavage procedure at Saint-Louis hospital, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), Università degli Studi di Padova = University of Padua (Unipd), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Centre National de la Recherche Scientifique (CNRS), Universität Duisburg-Essen = University of Duisburg-Essen [Essen], Radboud University [Nijmegen], and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, [SDV.BID.SPT]Life Sciences [q-bio]/Biodiversity/Systematics, Phylogenetics and taxonomy, [SDV.MP.MYC]Life Sciences [q-bio]/Microbiology and Parasitology/Mycology
Abstract

Quantitative real-time PCR (qPCR) is increasingly used to detect Pneumocystis jirovecii for the diagnosis of Pneumocystis pneumonia (PCP), but there are differences in the nucleic acids targeted, DNA only versus whole nucleic acid (WNA), and also the target genes for amplification. Through the Fungal qPCR Initiative, a working group of the International Society for Human and Animal Mycology, a multicentre and monocentre evaluation of PCP qPCR assays was performed. For the multicentre study, 16 reference laboratories from eight different countries, performing 20 assays analysed a panel consisting of two negative and three PCP positive samples. Aliquots were prepared by pooling residual material from 20 negative or positive- P. jirovecii bronchoalveolar lavage fluids (BALFs). The positive pool was diluted to obtain three concentrations (pure 1:1; 1:100; and 1:1000 to mimic high, medium, and low fungal loads respectively). The monocentre study compared five in-house and five commercial qPCR assays testing 19 individual BALFs on the same amplification platform. Across both evaluations and for all fungal loads, targeting WNA and the mitochondrial small sub-unit (mtSSU) provided the earliest Cq values, compared to only targeting DNA and the mitochondrial large subunit, the major surface glycoprotein or the beta-tubulin genes. Thus, Reverse Transcriptase-qPCR targeting the mtSSU gene could serve as a basis for standardizing the P. jirovecii load, which is essential if qPCR is to be incorporated into clinical care pathways as the reference method, accepting that additional parameters such as amplification platforms still need evaluation

Published
2019

54. Ethical and regulatory considerations in the use of individual participant data for studies of disease prediction

Author

Phillips, Bob, Ranasinghe, Neil, Stewart, Lesley A, Ammann, Roland A, Kuehne, Thomas, Niggli, Felix, Nadal, David, Hann, Ian, Sung, Lillian, Klaassen, Robert, Alexander, Sarah, Lehrnbecher, Thomas, Simon, Arne, Meidema, Karin, Tissing, Wim JE, Sutton, Alex J, Riley, Richard, Chisholm, Julia, Dommett, Rachel, Castagnola, Elio, Silva, Pamela, Tordecilla, Juan, Spassova, Maria, Hakim, Hana, Stryjewski, Glen, Tezcan, Gulsun, Kitanovski, Lidija, Bauters, Tiene, Laureys, Geneviève, Paesmann, Marianne, and Donnelly, J Peter

Published
2013
Full Text
View/download PDF

55. Antimicrobial therapy to prevent or treat oral mucositis

Author

Donnelly, J Peter, Bellm, Lisa A., Epstein, Joel B., Sonis, Stephen T., and Symonds, R Paul

Subjects
Peptides -- Analysis, Chemotherapy -- Analysis, Anti-infective agents -- Analysis, Stomatitis -- Prevention, Stomatitis -- Analysis, Radiotherapy -- Analysis, Cancer -- Chemotherapy, Cancer -- Analysis, Pain -- Care and treatment, Pain -- Analysis
Published
2003

57. CONTRIBUTORS

Author

Adkinson, N. Franklin, primary, Allen, David M., additional, Allos, Ban Mishu, additional, Amsden, Guy W., additional, Anderson, David A., additional, Andes, David R., additional, Aoki, Fred Y., additional, Apfalter, Petra M., additional, Apicella, Michael A., additional, Arias, Cesar A., additional, Augenbraun, Michael H., additional, Azar, Dimitri T., additional, Baddour, Larry M., additional, Baden, Lindsey R., additional, Baker, Carol J., additional, Ballard, Ronald C., additional, Ballow, Charles H., additional, Barnes, Scott D., additional, Baron, Miriam J., additional, Barouch, Dan H., additional, Barrett, Alan, additional, Bassin, Sarice L., additional, Batteiger, Byron E., additional, Baum, Stephen G., additional, Bayer, Arnold S., additional, Beckham, J. David, additional, Beekmann, Susan E., additional, Bell, Beth P., additional, Bennett, John E., additional, Berbari, Elie F., additional, Berman, Jonathan D., additional, Bertino, Joseph S., additional, Birdsall, Holly H., additional, Bisno, Alan L., additional, Biswas, Hope H., additional, Blackburn, Brian G., additional, Blaser, Martin J., additional, Blazes, David L., additional, Bleck, Thomas P., additional, Blijlevens, Nicole M.A., additional, Bobak, David A., additional, Bonnez, William, additional, Boothroyd, John C., additional, Borio, Luciana, additional, Bosque, Patrick J., additional, Boucher, Richard C., additional, Brause, Barry D., additional, Brown, Kevin E., additional, Brown, Patricia D., additional, Brown-Elliott, Barbara A., additional, Burd, Eileen M., additional, Burns, James E., additional, Bush, Larry M., additional, Calfee, David P., additional, Caplan, Ellis S., additional, Carael, Michel, additional, Carpenter, Charles C.J., additional, Caserta, Mary T., additional, Castagnola, Elio, additional, Chaisson, Richard E., additional, Chambers, Henry F., additional, Chapman, Stanley W., additional, Chappell, James D., additional, Chen, Sharon C-A., additional, Chopra, Sanjiv, additional, Chow, Anthony W., additional, Chroneou, Alexandra, additional, Cianciotto, Nicholas P., additional, Clark, Rebecca A., additional, Clark, Robert A., additional, Cohen, Jeffrey I., additional, Cohen, Myron S., additional, Cohen-Poradosu, Ronit, additional, Cohn, Susan E., additional, Connors, Mark, additional, Cono, Joanne, additional, Corey, Lawrence, additional, Cornett, Patricia A., additional, Cox, Heather L., additional, Craig, William A., additional, Craven, Donald E., additional, Crossley, Kent B., additional, Crump, John A., additional, Crumpacker, Clyde S., additional, Curran, James W., additional, Currie, Bart J., additional, Curry, Michael P., additional, Damon, Inger K., additional, Darouiche, Rabih O., additional, DeBiasi, Roberta L., additional, Deepe, George S., additional, del Rio, Carlos, additional, DeMuri, Gregory P., additional, Dennis, David T., additional, Densen, Peter, additional, De Pauw, Ben E., additional, Dermody, Terence S., additional, Dewar, Robin, additional, Diaz, James H., additional, Dieffenbach, Carl W., additional, Dienstag, Jules L., additional, Dolin, Raphael, additional, Donaldson, Scott H., additional, Donnelly, J. Peter, additional, Donnenberg, Michael S., additional, Donowitz, Gerald R., additional, Dormitzer, Philip R., additional, Drake, James M., additional, Dumler, J. Stephen, additional, Dummer, J. Stephen, additional, DuPont, Herbert L., additional, Durack, David T., additional, Durand, Marlene L., additional, Edelstein, Paul H., additional, Edmond, Michael B., additional, Edwards, John E., additional, Edwards, Morven S., additional, Eliopoulos, George M., additional, Engleberg, N. Cary, additional, Ernst, Joel D., additional, Fairhurst, Rick M., additional, Fairley, Jessica K., additional, Falkow, Stanley, additional, Falsey, Ann R., additional, Fauci, Anthony S., additional, Feinstone, Stephen M., additional, Fekete, Thomas, additional, Fey, Paul D., additional, Fine, Steven M., additional, Finegold, Sydney M., additional, Fishman, Neil O., additional, Fitzgerald, Daniel W., additional, Flores, Anthony R., additional, Fowler, Vance G., additional, Freedman, David O., additional, Friedlander, Arthur M., additional, Galgiani, John N., additional, Gallin, John I., additional, Gallo, Robert C., additional, Garrett, Wendy S., additional, Gelfand, Jeffrey A., additional, Gelone, Steven P., additional, Gershon, Anne A., additional, Gilbert, David N., additional, Gilligan, Peter H., additional, Glickman, Michael S., additional, Göbel, Ulf B., additional, Goldstein, Deborah, additional, Goldstein, Ellie J.C., additional, Gordin, Fred M., additional, Gotuzzo, Eduardo, additional, Graman, Paul S., additional, Graves, Margot, additional, Griffin, Patricia M., additional, Griffith, David E., additional, Guerrant, Richard L., additional, Haake, David A., additional, Haas, David W., additional, Hall, Caroline Breese, additional, Halperin, Scott, additional, Hammerschlag, Margaret R., additional, Handsfield, H. Hunter, additional, Haque, Rashidul, additional, Hartman, Barry J., additional, Hay, Roderick J., additional, Hayden, Frederick G., additional, Hedberg, Craig W., additional, Henderson, David K., additional, Henderson, Donald A., additional, Hendley, J. Owen, additional, Hewlett, Erik L., additional, High, Kevin P., additional, Hill, Adrian V.S., additional, Hill, David R., additional, Hinman, Alan R., additional, Hirsch, Martin S., additional, Hodges, Lisa S., additional, Holland, Steven M., additional, Hook, Edward W., additional, Hooper, David C., additional, Hooton, Thomas M., additional, Horsburgh, C. Robert, additional, Hospenthal, Duane R., additional, Hughes, James M., additional, Hughes, Molly A., additional, Huston, Christopher D., additional, Hynes, Noreen A., additional, Iredell, Jonathan R., additional, Janda, J. Michael, additional, Johannsen, Eric C., additional, Johnson, Warren D., additional, Kashuba, Angela D.M., additional, Kasper, Dennis L., additional, Kaye, Donald, additional, Kaye, Keith S., additional, Kaye, Kenneth M., additional, Kazura, James W., additional, Kenny, George E., additional, Keystone, Jay S., additional, Khabbaz, Rima F., additional, King, Charles H., additional, Kirchhoff, Louis V., additional, Klein, Jerome O., additional, Knoll, Bettina M., additional, Knowlton, Kirk U., additional, Kohlhoff, Stephan A., additional, Könönen, Eija, additional, Kontoyiannis, Dimitrios P., additional, Koralnik, Igor J., additional, Koshy, Anita A., additional, Kotton, Camille Nelson, additional, Kovacs, Joseph A., additional, Kozarsky, Phyllis, additional, Koziel, Margaret James, additional, Krieger, John N., additional, Kuehnert, Matthew J., additional, LeDuc, James W., additional, Lee, Laura M., additional, Leggett, James E., additional, Lescano, Andres G., additional, Levett, Paul N., additional, Levine, Donald P., additional, Levison, Matthew E., additional, Lewis, Russell E., additional, Liles, W. Conrad, additional, Lima, Aldo A.M., additional, Litman, Nathan, additional, Lorber, Bennett, additional, Lutwick, Larry I., additional, MacGregor, Rob Roy, additional, Mackowiak, Philip A., additional, Madoff, Lawrence C., additional, Magill, Alan J., additional, Maguire, James H., additional, Maldarelli, Frank, additional, Mandell, Lionel A., additional, Mann, Barbara J., additional, Markoff, Lewis, additional, Marrazzo, Jeanne M., additional, Marrie, Thomas J., additional, Marth, Thomas, additional, Martin, Gregory J., additional, Maschmeyer, Georg, additional, Masur, Henry, additional, Mawle, Alison, additional, Mayer, Kenneth H., additional, McBride, John T., additional, McCormack, William M., additional, McIntosh, Kenneth, additional, Mead, Paul S., additional, Meyer, Daniel K., additional, Meyers, Burt R., additional, Miller, Mark A., additional, Miller, Samuel I., additional, Mitchell, David H., additional, Modlin, John F., additional, Moellering, Robert C., additional, Moir, Susan, additional, Montgomery, Joel M., additional, Montoya, José G., additional, Moore, Thomas A., additional, Moreillon, Philippe, additional, Morrell, Dean S., additional, Morris, J. Glenn, additional, Morse, Caryn Gee, additional, Moseley, Robin, additional, Muder, Robert R., additional, Munford, Robert S., additional, Murphy, Edward L., additional, Murphy, Timothy F., additional, Murray, Barbara E., additional, Murray, Clinton K., additional, Murray, Patrick R., additional, Musher, Daniel M., additional, Nannini, Esteban C., additional, Nash, Theodore E., additional, Nauseef, William M., additional, Neill, Marguerite A., additional, O'Donnell, Judith A., additional, Ohl, Christopher A., additional, Okhuysen, Pablo C., additional, Onderdonk, Andrew B., additional, Opal, Steven M., additional, Orenstein, Walter A., additional, Osman, Douglas R., additional, Osterholm, Michael T., additional, Ostroff, Stephen M., additional, Oxman, Michael N., additional, Page, Andrea V., additional, Palmore, Tara N., additional, Pamer, Eric G., additional, Pappas, Peter G., additional, Pasternack, Mark S., additional, Patterson, Thomas F., additional, Pavan-Langston, Deborah, additional, Pegues, David A., additional, Penn, Robert L., additional, Perfect, John R., additional, Perlman, Stanley, additional, Peters, C.J., additional, Peterson, Phillip K., additional, Petri, William A., additional, Petti, Cathy A., additional, Pickering, Larry K., additional, Pier, Gerald B., additional, Pillai, Satish K., additional, Piot, Peter, additional, Plaeger, Susan F., additional, Polk, Ronald E., additional, Pop-Vicas, Aurora, additional, Powers, John H., additional, Punturieri, Antonello, additional, Que, Yok-ai, additional, Rabinowitz, Ronald P., additional, Rabizadeh, Shervin, additional, Ramphal, Reuben, additional, Raoult, Didier, additional, Ravdin, Jonathan I., additional, Ray, Stuart C., additional, Reboli, Annette C., additional, Reddy, Pavani, additional, Reichman, Richard C., additional, Reitz, Marvin S., additional, Relman, David A., additional, Renault, Cybèle A., additional, Restrepo, Angela, additional, Rex, John H., additional, Reynolds, Herbert Y., additional, Rhee, Elizabeth G., additional, Rhee, Kyu Y., additional, Rotz, Lisa D., additional, Ruoff, Kathryn L., additional, Rupp, Mark E., additional, Rupprecht, Charles E., additional, Russo, Thomas A., additional, Rutala, William A., additional, Salvatore, Mirella, additional, Saulsbury, Frank T., additional, Savoia, Maria C., additional, Sax, Paul E., additional, Scheld, W. Michael, additional, Schiffer, Joshua T., additional, Schlossberg, David, additional, Schneider, Thomas, additional, Schwebke, Jane R., additional, Sears, Cynthia L., additional, Seas, Carlos, additional, Sepkowitz, Kent A., additional, Septimus, Edward J., additional, Siberry, George K., additional, Sifri, Costi D., additional, Singh, Nina, additional, Singh, Upinder, additional, Sinner, Scott W., additional, Sivapalasingam, Sumathi, additional, Slater, Leonard N., additional, Smulian, A. George, additional, Sobel, Jack D., additional, Sodha, Samir V., additional, Sohail, M. Rizwan, additional, Solomon, Tom, additional, Song, Yuli, additional, Soper, David E., additional, Sorrell, Tania C., additional, Sparling, P. Frederick, additional, Stamm, Walter E., additional, Steckelberg, James M., additional, Steere, Allen C., additional, Steigbigel, Neal H., additional, Steinberg, James P., additional, Steiner, Theodore S., additional, Sterling, Timothy R., additional, Stevens, David A., additional, Stevens, Dennis L., additional, Strahilevitz, Jacob, additional, Stratton, Charles W., additional, Suffredini, Anthony F., additional, Suh, Kathryn N., additional, Sulkowski, Mark S., additional, Sullivan, Donna C., additional, Swartz, Morton N., additional, Talbot, Thomas R., additional, Tan, C. Sabrina, additional, Thielman, Nathan M., additional, Thio, Chloe Lynn, additional, Thomas, David L., additional, Thomas, Lora D., additional, Thorner, Anna R., additional, Tice, Alan D., additional, Tobón, Angela María, additional, Tramont, Edmund C., additional, Treanor, John J., additional, N. Tsibris, Athe M., additional, Tunkel, Allan R., additional, Turner, Ronald B., additional, Tyler, Kenneth L., additional, van de Beek, Diederik, additional, Vannier, Edouard G., additional, Van Schooneveld, Trevor C., additional, Vaughn, David W., additional, Viscoli, Claudio, additional, Volberding, Paul A., additional, Wald, Ellen R., additional, Walker, David H., additional, Wallace, Richard J., additional, Walsh, Edward E., additional, Walzer, Peter D., additional, Wanke, Christine A., additional, Washburn, Ronald G., additional, Wasley, Annemarie, additional, Waters, Valerie, additional, Weber, David J., additional, Weinberg, Arnold N., additional, Weinberg, Geoffrey A., additional, Weinmann, Gail G., additional, Weisdorf, Daniel J., additional, Weiss, Louis M., additional, Weiss, Michael E., additional, Welch, David F., additional, Wellems, Thomas E., additional, Wenzel, Richard P., additional, Wharton, Melinda, additional, White, A. Clinton, additional, Whitley, Richard J., additional, Wilson, Kenneth H., additional, Wilson, Walter R., additional, Witebsky, Frank G., additional, Wolfgang, Matthew C., additional, Wright, Peter F., additional, Young, Edward J., additional, Young, Jo-Anne H., additional, Zhang, Jie Lin, additional, Zinner, Stephen H., additional, and Zurlo, John J., additional

Published
2010
Full Text
View/download PDF

59. When to change treatment of acute invasive aspergillosis: an expert viewpoint.

Author

Slavin, Monica A, Chen, Yee-Chun, Cordonnier, Catherine, Cornely, Oliver A, Cuenca-Estrella, Manuel, Donnelly, J Peter, Groll, Andreas H, Lortholary, Olivier, Marty, Francisco M, Nucci, Marcio, Rex, John H, Rijnders, Bart J A, Thompson, George R, Verweij, Paul E, White, P Lewis, Hargreaves, Ruth, Harvey, Emma, and Maertens, Johan A

Subjects
ASPERGILLOSIS, IMMUNOSUPPRESSIVE agents, BRONCHOALVEOLAR lavage, CLINICAL deterioration, COMPUTED tomography, IMMUNITY, ASPERGILLOSIS diagnosis, POLYSACCHARIDES, ANTIFUNGAL agents, RESEARCH, BODY fluids, IMMUNOCOMPROMISED patients, EVALUATION research, PULMONARY aspergillosis, COMPARATIVE studies, RESEARCH funding
Abstract

Invasive aspergillosis (IA) is an acute infection affecting patients who are immunocompromised, as a result of receiving chemotherapy for malignancy, or immunosuppressant agents for transplantation or autoimmune disease. Whilst criteria exist to define the probability of infection for clinical trials, there is little evidence in the literature or clinical guidelines on when to change antifungal treatment in patients who are receiving prophylaxis or treatment for IA. To try and address this significant gap, an advisory board of experts was convened to develop criteria for the management of IA for use in designing clinical trials, which could also be used in clinical practice. For primary treatment failure, a change in antifungal therapy should be made: (i) when mycological susceptibility testing identifies an organism from a confirmed site of infection, which is resistant to the antifungal given for primary therapy, or a resistance mutation is identified by molecular testing; (ii) at, or after, 8 days of primary antifungal treatment if there is increasing serum galactomannan, or galactomannan positivity in serum, or bronchoalveolar lavage fluid when the antigen was previously undetectable, or there is sudden clinical deterioration, or a new clearly distinct site of infection is detected; and (iii) at, or after, 15 days of primary antifungal treatment if the patient is clinically stable but with ≥2 serum galactomannan measurements persistently elevated compared with baseline or increasing, or if the original lesions on CT or other imaging, show progression by >25% in size in the context of no apparent change in immune status. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

64. Reply to Luppi et al

Author

Wingard, John R, primary, Maertens, Johan, additional, Pagano, Livio, additional, Chen, Sharon C-A, additional, Pappas, Peter G, additional, and Donnelly, J Peter, additional

Published
2020
Full Text
View/download PDF

65. Reply to Herbrecht et al

Author

Baddley, John W, primary, Morrissey, C Orla, additional, Shaefer-Prokop, Cornelia, additional, Chen, Sharon C-A, additional, Pappas, Peter G, additional, and Donnelly, J Peter, additional

Published
2020
Full Text
View/download PDF

67. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium

Author

Donnelly, J Peter, primary, Chen, Sharon C, additional, Kauffman, Carol A, additional, Steinbach, William J, additional, Baddley, John W, additional, Verweij, Paul E, additional, Clancy, Cornelius J, additional, Wingard, John R, additional, Lockhart, Shawn R, additional, Groll, Andreas H, additional, Sorrell, Tania C, additional, Bassetti, Matteo, additional, Akan, Hamdi, additional, Alexander, Barbara D, additional, Andes, David, additional, Azoulay, Elie, additional, Bialek, Ralf, additional, Bradsher, Robert W, additional, Bretagne, Stephane, additional, Calandra, Thierry, additional, Caliendo, Angela M, additional, Castagnola, Elio, additional, Cruciani, Mario, additional, Cuenca-Estrella, Manuel, additional, Decker, Catherine F, additional, Desai, Sujal R, additional, Fisher, Brian, additional, Harrison, Thomas, additional, Heussel, Claus Peter, additional, Jensen, Henrik E, additional, Kibbler, Christopher C, additional, Kontoyiannis, Dimitrios P, additional, Kullberg, Bart-Jan, additional, Lagrou, Katrien, additional, Lamoth, Frédéric, additional, Lehrnbecher, Thomas, additional, Loeffler, Jurgen, additional, Lortholary, Olivier, additional, Maertens, Johan, additional, Marchetti, Oscar, additional, Marr, Kieren A, additional, Masur, Henry, additional, Meis, Jacques F, additional, Morrisey, C Orla, additional, Nucci, Marcio, additional, Ostrosky-Zeichner, Luis, additional, Pagano, Livio, additional, Patterson, Thomas F, additional, Perfect, John R, additional, Racil, Zdenek, additional, Roilides, Emmanuel, additional, Ruhnke, Marcus, additional, Prokop, Cornelia Schaefer, additional, Shoham, Shmuel, additional, Slavin, Monica A, additional, Stevens, David A, additional, Thompson, George R, additional, Vazquez, Jose A, additional, Viscoli, Claudio, additional, Walsh, Thomas J, additional, Warris, Adilia, additional, Wheat, L Joseph, additional, White, P Lewis, additional, Zaoutis, Theoklis E, additional, and Pappas, Peter G, additional

Published
2019
Full Text
View/download PDF

68. The Fungal PCR Initiative's evaluation of in-house and commercial Pneumocystis jirovecii qPCR assays: Toward a standard for a diagnostics assay

Author

Gits-Muselli, Maud, primary, White, P Lewis, additional, Mengoli, Carlo, additional, Chen, Sharon, additional, Crowley, Brendan, additional, Dingemans, Gijs, additional, Fréalle, Emilie, additional, L Gorton, Rebecca, additional, Guiver, Malcom, additional, Hagen, Ferry, additional, Halliday, Catriona, additional, Johnson, Gemma, additional, Lagrou, Katrien, additional, Lengerova, Martina, additional, Melchers, Willem J G, additional, Novak-Frazer, Lily, additional, Rautemaa-Richardson, Riina, additional, Scherer, Emeline, additional, Steinmann, Joerg, additional, Cruciani, Mario, additional, Barnes, Rosemary, additional, Donnelly, J Peter, additional, Loeffler, Juergen, additional, Bretagne, Stéphane, additional, and Alanio, Alexandre, additional

Published
2019
Full Text
View/download PDF

73. Monitoring myeloablative therapy-induced small bowel toxicity by serum citrulline concentration

Author

Lutgens, Ludy C.H.W., Blijlevens, Nicole M.A., Deutz, Nicolaas E.P., Donnelly, J. Peter, Lambin, Philippe, and de Pauw, Ben E.

Subjects
Citrulline -- Research, Citrulline -- Analysis, Permeability -- Research, Permeability -- Analysis, Intestinal mucosa -- Complications and side effects, Intestinal mucosa -- Research, Intestinal mucosa -- Care and treatment, Intestinal mucosa -- Analysis, Small intestine cancer -- Research, Small intestine cancer -- Care and treatment, Small intestine cancer -- Diagnosis, Small intestine cancer -- Analysis, Health
Published
2005

74. Empiric therapy in the persistently febrile patient with neutropenia: caspofungin vs liposomal amphotericin

Author

Deresinski, Stan and Donnelly, J. Peter

Subjects
Amphotericin B -- Drug therapy, Neutropenia -- Care and treatment, Antifungal agents, Health
Abstract

Synopsis: Overall, caspofungin was at least as effective as liposomal amphotericin B for empiric therapy in persistently febrile neutropenic patients. Caspofungin therapy was associated with greater survival 7 days after [...]

Published
2004

75. Perspectives on cancer therapy-induced mucosal injury

Author

Sonis, Stephen T., Elting, L.S., Keefe, D., Peterson, D.E., Schubert, Mark, Hauer-Jensen, Martin, Bekele, B. Nebiyou, Raber-Durlacher, Judith, Donnelly, J. Peter, and Rubenstein, Edward, B.

Subjects
Mucociliary system -- Research, Mucociliary system -- Diseases, Cancer -- Care and treatment, Cancer -- Research, Cancer -- Complications and side effects, Health
Published
2004

78. Halo sign and improved outcome

Author

Verweij, Paul E., van Die, Lya, Donnelly, J. Peter, Greene, Reginald E., Schlamm, Haran T., Oestmann, Jorg-W., Stark, Paul, Durand, Christine, Lortholary, Olivier, Wingard, John R., Herbrecht, Raoul, Ribaud, Patricia, Patterson, Thomas F., Troke, Peter F., Denning, David W., Bennett, John E., De Pauw, Ben E., and Rubin, Robert H.

Subjects
Pulmonary aspergillosis -- Care and treatment, Amphotericin B -- Dosage and administration, Amphotericin B -- Research, Health, Health care industry
Published
2007

82. Safety and tolerability of the antimicrobial peptide human lactoferrin 1-11 (hLF1-11)

Author

Blijlevens Nicole MA, van Iersel Thijs MP, van der Velden Walter JFM, and Donnelly J Peter

Subjects
Medicine
Abstract

Abstract Background The treatment of patients with haematological malignancies by means of haematopoietic stem cell transplantation (HSCT) is often accompanied by life threatening infections. With emerging antimicrobial resistance there is an increased need for new agents, with a beneficial safety profile. Therefore we evaluated the safety of the promising new antimicrobial peptide human lactoferrrin 1-11 (hLF1-11) in healthy volunteers and patients. Methods We undertook a sequential, randomised, double-blind, placebo-controlled study using ascending single (0.005, 0.05, 0.5, 5 mg) and multiple intravenous doses (0.5, 5 mg) in healthy volunteers, and open-label, single intravenous 5 mg doses in autologous HSCT recipients. Results Single and multiple doses of hLF1-11 were tolerable up to 5 mg intravenously in healthy volunteers, while 5 mg single dose was tolerable in patients. Elevations in transaminases possibly related to treatment were reversible and not serious. Conclusion The new antimicrobial hLF1-11 is well tolerated in healthy volunteers with repeated daily doses up to 5 mg. The side-effect profile is very favourable for an antimicrobial, the only undesirable effect being a possible elevation of transaminases, which may be related to hLF1-11 although the current data do not allow conclusive interpretation of treatment relationship. A lower dose is recommended for the forthcoming multiple dosing studies in HSCT patients. Trial registration ClinicalTrials.gov: nct00509938.

Published
2009
Full Text
View/download PDF

83. Ceftazidime compared with piperacillin and tobramycin for the empiric treatment of fever in neutropenic patients with cancer: a multicenter randomized trial

Author

De Pauw, Ben E., Deresinski, Stanley C., Feld, Ronald, Lane-Allman, Elizabeth F., and Donnelly, J. Peter

Subjects
Antipyretics -- Evaluation, Ceftazidime -- Evaluation, Piperacillin -- Evaluation, Tobramycin -- Evaluation, Fever -- Drug therapy, Cancer patients -- Care and treatment, Health
Abstract

* Objective: To compare piperacillin and tobramycin with ceftazidime alone for the empiric treatment of fever in the neutropenic patient without evidence of skin infections or anaerobic infections. * Design: A multicenter, randomized, controlled trial. * Patients: 876 febrile, neutropenic episodes in 696 patients (83% acute leukemia or bone marrow transplantation); 92 episodes were excluded from analysis because of protocol violation. * Interventions: Patients received either intravenous ceftazidime (2 g every 8 h) or piperacillin (12 to 18 g/d in 4 to 6 divided doses plus tobramycin (1.7 to 2.0 mg/kg body weight every 8 h). Treatment could be modified at any time at the discretion of the investigator. * Measurements: Percentage of satisfactory response, eradication of the infecting organism, development of superinfections, and occurrence of adverse events. * Results: As a single agent, ceftazidime was as effective as the combination of piperacillin and tobramycin (62.7% satisfactory responses compared with 61.1%; odds ratio, 1.07; 95% CI, 0.79 to 1.44; P > 0.2). Equivalent responses were also obtained in episodes of profound neutropenia (odds ratio, 0.76; CI, 0.43 to 1.33; P > 0.2). Infectious mortality was 6% for ceftazidime and 8% for the combination therapy. Eradication of the infecting organisms was achieved in 79% of bacteremic episodes treated with ceftazidime compared with 68% of the episodes treated with the combination therapy (odds ratio, 1.76; CI, 0.92 to 3.38; P = 0.08), and rates for gram-negative rod bacteremia were also similar (95% compared with 77%; odds ratio, 5.25; CI, 1.0 to 27.5; P = 0.03). Superinfections developed in 38 episodes in each group. An adverse event occurred in 8% of episodes treated with ceftazidime compared with 20% of episodes treated with combination therapy P < 0.001). * Conclusion: Ceftazidime alone was as effective but safer than the combination of piperacillin and tobramycin for the empiric treatment of febrile, neutropenic patients, even those with profound and prolonged granulocytopenia., Ceftazidime has been shown to be safer than and just as effective as the combination of piperacillin and tobramycin in treating cancer patients with fever and neutropenia who do not have a staphylococcal or anaerobic infection. Neutropenia is a reduced level of white blood cells that is also known as granulocytopenia and agranulocytosis. Most of the 696 patients studied had acute leukemia or a bone marrow transplant. The combination of piperacillin and tobramycin had a much higher rate of toxicity than did ceftazidime, especially on kidney function. Resistance to ceftazidime developed in only 3% of the patients. An adverse event occurred in 8% of the cases in which ceftazidime was used, as opposed to 20% of the cases with piperacillin and tobramycin therapy.

Published
1994

84. still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J.G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stephane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Bruggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valerie, Roilides, Emmanuel, on behalf of the Fifth European Conference on Infections in Leukemia (ECIL-5), The European Group for Blood and Marrow Transplantation (EBMT), The European Organization for Research and Treatment of Cancer (EORTC), Immunocompromised Host Society (ICHS) and The European LeukemiaNet (ELN), Instituto de Higiene e Medicina Tropical (IHMT), Global Health and Tropical Medicine (GHTM), and TB, HIV and opportunistic diseases and pathogens (THOP)

Subjects
Carinii-pneumonia, Aids, Infectious Diseases, ECIL guidelines, SDG 3 - Good Health and Well-being, Outbreaks, Infection, Infants, Management
Abstract

Made available in DSpace on 2021-09-24T00:56:32Z (GMT). No. of bitstreams: 0 Previous issue date: 2017-04-01 publishersversion published

Published
2017

85. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients-authors' response

Author

Cordonnier, Catherine, Alanio, Alexandre, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stéphane, Maertens, Johan, Agrawal, Samir, Akova, Murat, Aljurf, Mahmoud, Averbuch, Dina, Berg, Thomas, Blennow, Ola, Brüggemann, Roger, Calandra, Thierry, Castagnola, Elio, Cornely, Oliver, De La Camara, Rafael, Drgona, Lubos, Duarte, Rafael, Engelhard, Dan, Girmenia, Corrado, Hargreaves, Ruth, Herbrecht, Raoul, Hirsch, Hans, Hubacek, Petr, Kibbler, Christopher, Klyasova, Galina, Kouba, Michal, Kullberg, Bart-Jan, Ljungman, Per, Mallet, Vincent, Marchetti, Oscar, Mikulska, Malgorzata, Munoz, Patricia, Orasch, Christina, Pagano, Livio, Pagliuca, Antonio, Penack, Olaf, Pettrikos, George, Racil, Zdenek, Ribaud, Patricia, Rizzi-Puechal, Valérie, Roilides, Emmanuel, Sinko, Janos, Skiada, Anna, Slavin, Monica, Styczynski, Jan, Tissot, Frederic, Tweddle, Lorraine, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Viscoli, Claudio, Ward, Katherine, and Wood, Craig

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, 030106 microbiology, HIV Infections, Pneumocystis carinii, 03 medical and health sciences, Acquired immunodeficiency syndrome (AIDS), Hematologic Neoplasms, Humans, Pneumonia, Pneumocystis, Stem Cell Transplantation, Pharmacology, Pharmacology (medical), Infectious Diseases, Medicine, In patient, Intensive care medicine, hematopoietic stem cell transplant, business.industry, Pneumocystis, PNEUMOCYSTIS JIROVECI, Pneumocystis jiroveci, infection, hematopoietic stem cell transplant, Pneumocystis jirovecii Pneumonia, Pneumocystis jiroveci, Pneumonia, medicine.disease, infection, Women's cancers Radboud Institute for Health Sciences [Radboudumc 17], Stem cell, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

Contains fulltext : 169784.pdf (Publisher’s version ) (Closed access)

Published
2017

88. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Maertens, Johan, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg-Larsen, Jannik, Matos, Olga, Bretagne, Stã©phane, Cordonnier, Catherine, Agrawal, Samir, Kibbler, Christopher, Pagliuca, SIMONE ANTONIO, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld-Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart-Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, Malgorzata, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi-Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Department of Hematology, University Hospital Gasthuisberg, G.B. Rossi Hospital, Verona University, Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Radboud university [Nijmegen], Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Lausanne University Hospital, Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Rigshospitalet [Copenhagen], Copenhagen University Hospital, Instituto de Higiene e Medicina Tropical (IHMT), Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Centre National de Référence Mycologie et Antifongiques-Mycologie Moléculaire (CNRMA), Institut Pasteur [Paris], Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer., University Hospital Gasthuisberg [Leuven], Università degli studi di Verona = University of Verona (UNIVR), Radboud University [Nijmegen], Julius-Maximilians-Universität Würzburg (JMU), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)

Subjects
0301 basic medicine, Microbiology (medical), Antifungal Agents, [SDV]Life Sciences [q-bio], 030106 microbiology, Pneumocitis jirovecii, Chemoprevention, Trimethoprim, Immunocompromised Host, 03 medical and health sciences, 0302 clinical medicine, Trimethoprim, Sulfamethoxazole Drug Combination, Humans, Pharmacology (medical), Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Sulfamethoxazole Drug Combination, Pneumocystis, Hematologic Neoplasms, Pneumonia, Pneumocystis, Stem Cell Transplantation, Transplant Recipients, Infectious Diseases, immunocomrpomised host, pneumonia, Pneumocitis jirovecii, Pneumonia, 3. Good health, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], 030220 oncology & carcinogenesis, immunocomrpomised host, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

Contains fulltext : 172373.pdf (Publisher’s version ) (Closed access) The 5th European Conference on Infections in Leukaemia (ECIL-5) meeting aimed to establish evidence-based recommendations for the prophylaxis of Pneumocystis jirovecii pneumonia (PCP) in non-HIV-infected patients with an underlying haematological condition, including allogeneic HSCT recipients. Recommendations were based on the grading system of the IDSA. Trimethoprim/sulfamethoxazole given 2-3 times weekly is the drug of choice for the primary prophylaxis of PCP in adults ( A-II: ) and children ( A-I: ) and should be given during the entire period at risk. Recent data indicate that children may benefit equally from a once-weekly regimen ( B-II: ). All other drugs, including pentamidine, atovaquone and dapsone, are considered second-line alternatives when trimethoprim/sulfamethoxazole is poorly tolerated or contraindicated. The main indications of PCP prophylaxis are ALL, allogeneic HSCT, treatment with alemtuzumab, fludarabine/cyclophosphamide/rituximab combinations, >4 weeks of treatment with corticosteroids and well-defined primary immune deficiencies in children. Additional indications are proposed depending on the treatment regimen.

Published
2016

89. ECIL guidelines for the diagnosis of Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients

Author

Alanio, Alexandre, Hauser, Philippe M., Lagrou, Katrien, Melchers, Willem J. G., Helweg Larsen, Jannik, Matos, Olga, Cesaro, Simone, Maschmeyer, Georg, Einsele, Hermann, Donnelly, J. Peter, Cordonnier, Catherine, Maertens, Johan, Bretagne, Stã©phane, Agrawal, Samir, Kibbler, Christopher, Pagliuca, Antonio, Ward, Katherine, Akova, Murat, Herbrecht, Raoul, Mallet, Vincent, Ribaud, Patricia, Aljurf, Mahmoud, Averbuch, Dina, Engelhard, Dan, Berg, Thomas, Cornely, Oliver, Penack, Olaf, van Boemmel, Florian, von Lilienfeld Toal, Marie, Blennow, Ola, Ljungman, Per, Bruggemann, Roger, Donnelly, Peter, Kullberg, Bart Jan, Melchers, Willem, Calandra, Thierry, Hirsch, Hans, Marchetti, Oscar, Orasch, Christina, Tissot, Frederic, Castagnola, Elio, Girmenia, Corrado, Mikulska, MALGORZATA KAROLINA, Pagano, Livio, Viscoli, Claudio, De La Camara, Rafael, Duarte, Rafael, Munoz, Patricia, Drgona, Lubos, Hargreaves, Ruth, Hubacek, Petr, Kouba, Michal, Racil, Zdenek, Klyasova, Galina, Pettrikos, George, Roilides, Emmanuel, Skiada, Anna, Rizzi Puechal, Valã©rie, Sinko, Janos, Slavin, Monica, Styczynski, Jan, Tweddle, Lorraine, Wood, Craig, Centre National de Référence des Mycoses invasives et antifongiques - Mycologie moléculaire (CNRMA), Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), Université Paris Diderot - Paris 7 (UPD7), Laboratoire de Parasitologie-Mycologie [CHU Saint Louis, Paris], Groupe Hospitalier Saint Louis - Lariboisière - Fernand Widal [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Mycologie moléculaire, Université de Lausanne = University of Lausanne (UNIL), Université Catholique de Louvain = Catholic University of Louvain (UCL), Radboud University [Nijmegen], Rigshospitalet [Copenhagen], Copenhagen University Hospital, Universidade Nova de Lisboa = NOVA University Lisbon (NOVA), Università degli studi di Verona = University of Verona (UNIVR), Medizinische Klinik, Hämatologie und Onkologie, Klinikum Ernst von Bergmann, Julius Maximilians University Wurzburg, Julius-Maximilians-Universität Würzburg [Wurtzbourg, Allemagne] (JMU), Service d'hématologie clinique, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Department of Hematology, University Hospital Gasthuisberg [Leuven], The ECIL-5 meeting was supported by unrestricted educational grants from Astellas Pharma, Gilead Sciences, Merck, and Pfizer, Université de Lausanne (UNIL), Radboud university [Nijmegen], G.B. Rossi Hospital, Verona University, University Hospital Gasthuisberg, Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS), and Julius-Maximilians-Universität Würzburg (JMU)

Subjects
0301 basic medicine, Microbiology (medical), medicine.medical_specialty, [SDV]Life Sciences [q-bio], 030106 microbiology, Dapsone, Pneumocystis carinii, 03 medical and health sciences, Immunocompromised Host, 0302 clinical medicine, Diagnostic Tests, Internal medicine, medicine, Pneumocistis jirovecii, Humans, Routine, Pharmacology (medical), 030212 general & internal medicine, Intensive care medicine, Pharmacology, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], business.industry, Diagnostic Tests, Routine, Pneumocystis, Pneumonia, Pneumocystis, Pneumonia, medicine.disease, Trimethoprim, Transplant Recipients, 3. Good health, Fludarabine, Regimen, lnfectious Diseases and Global Health Radboud Institute for Health Sciences [Radboudumc 4], Infectious Diseases, Hematologic Neoplasms, Alemtuzumab, Rituximab, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5], [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Pentamidine, medicine.drug, immunocompromised host, pneumonia, Pneumocistis jirovecii, Stem Cell Transplantation
Abstract

Item does not contain fulltext The Fifth European Conference on Infections in Leukaemia (ECIL-5) convened a meeting to establish evidence-based recommendations for using tests to diagnose Pneumocystis jirovecii pneumonia (PCP) in adult patients with haematological malignancies. Immunofluorescence assays are recommended as the most sensitive microscopic method (recommendation A-II: ). Real-time PCR is recommended for the routine diagnosis of PCP ( A-II: ). Bronchoalveolar lavage (BAL) fluid is recommended as the best specimen as it yields good negative predictive value ( A-II: ). Non-invasive specimens can be suitable alternatives ( B-II: ), acknowledging that PCP cannot be ruled out in case of a negative PCR result ( A-II: ). Detecting beta-d-glucan in serum can contribute to the diagnosis but not the follow-up of PCP ( A-II: ). A negative serum beta-d-glucan result can exclude PCP in a patient at risk ( A-II: ), whereas a positive test result may indicate other fungal infections. Genotyping using multilocus sequence markers can be used to investigate suspected outbreaks ( A-II: ). The routine detection of dihydropteroate synthase mutations in cases of treatment failure is not recommended ( B-II: ) since these mutations do not affect response to high-dose co-trimoxazole. The clinical utility of these diagnostic tests for the early management of PCP should be further assessed in prospective, randomized interventional studies.

Published
2016

90. Comparison of Nonculture Blood-Based Tests for Diagnosing Invasive Aspergillosis in an Animal Model

Author

White, P. Lewis, Wiederhold, Nathan P., Loeffler, Juergen, Najvar, Laura K., Melchers, Willem, Herrera, Monica, Bretagne, Stephane, Wickes, Brian, Kirkpatrick, William R., Barnes, Rosemary Ann, Donnelly, J. Peter, Patterson, Thomas F., and Warnock, D. W.

Subjects
Male, 0301 basic medicine, Microbiology (medical), medicine.medical_specialty, Time Factors, beta-Glucans, Guinea Pigs, 030106 microbiology, Mycology, Aspergillosis, Polymerase Chain Reaction, Sensitivity and Specificity, Mannans, 03 medical and health sciences, Galactomannan, chemistry.chemical_compound, Blood serum, In vivo, Internal medicine, Animals, Medicine, ddc:610, Stage (cooking), Whole blood, Invasive Pulmonary Aspergillosis, Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17], Diagnostic Tests, Routine, business.industry, Area under the curve, Galactose, medicine.disease, Clinical trial, Disease Models, Animal, Blood, Molecular Diagnostic Techniques, chemistry, Immunology, Proteoglycans, business, Inflammatory diseases Radboud Institute for Molecular Life Sciences [Radboudumc 5]
Abstract

The European Aspergillus PCR Initiative (EAPCRI) has provided recommendations for the PCR testing of whole blood (WB) and serum/plasma. It is important to test these recommended protocols on nonsimulated “ in vivo ” specimens before full clinical evaluation. The testing of an animal model of invasive aspergillosis (IA) overcomes the low incidence of disease and provides experimental design and control that is not possible in the clinical setting. Inadequate performance of the recommended protocols at this stage would require reassessment of methods before clinical trials are performed and utility assessed. The manuscript describes the performance of EAPCRI protocols in an animal model of invasive aspergillosis. Blood samples taken from a guinea pig model of IA were used for WB and serum PCR. Galactomannan and β- d -glucan detection were evaluated, with particular focus on the timing of positivity and on the interpretation of combination testing. The overall sensitivities for WB PCR, serum PCR, galactomannan, and β- d -glucan were 73%, 65%, 68%, and 46%, respectively. The corresponding specificities were 92%, 79%, 80%, and 100%, respectively. PCR provided the earliest indicator of IA, and increasing galactomannan and β- d -glucan values were indicators of disease progression. The combination of WB PCR with galactomannan and β- d -glucan proved optimal (area under the curve [AUC], 0.95), and IA was confidently diagnosed or excluded. The EAPRCI-recommended PCR protocols provide performance comparable to commercial antigen tests, and clinical trials are warranted. By combining multiple tests, IA can be excluded or confirmed, highlighting the need for a combined diagnostic strategy. However, this approach must be balanced against the practicality and cost of using multiple tests.

Published
2016

92. Clinical research in the lay press: irresponsible journalism raises a huge dose of doubt

Author

Anaissie, Elias J., Segal, Brahm H., Graybill, John R., Arndt, Carola, Perfect, John R., Kleinberg, Michael, Pappas, Peter, Benjamin, Danny, Rubin, Robert, Aberg, Judith A., Adderson, Elisabeth E., Adler-Shohet, Felice C., Akan, Hamdi, Akova, Murat, Almyroudis, Nikolaos G., Alexander, Barbara D., Andes, David, Arrieta, Antonio, Baddley, John W., Barron, Michelle A., Belzberg, Howard, Boucher, Helen W., Boyce, Thomas G., Casadevall, Arturo, Chandrasekar, P.H., Cleary, John D., Cordonnier, Catherine, Cornely, Oliver A., Cuenca-Estrella, Manuel, Daly, Jennifer S., Daoura, Nicholas, Denning, David W., dePauw, Ben, Repentigny, Louis de, Dignani, Maria Cecilia, Dismukes, William E., Donnelly, J. Peter, Donowitz, Gerald R., Dupont, Bertrand, Drusano, George, Ellis, Michael, Espinel-Ingroff, Ana, Fishman, Jay A., Fleming, Rhonda, Forrest, Graeme, Ghannoum, Mahmoud, Goldman, Mitchell, Grazziutti, Monica, Greene, John N., Greenberg, Richard N., Gubbins, Paul O., Hadley, Susan, Herbrecht, Raoul, Hiemenz, John W., Hope, William, Hospenthal, Durane R., Husain, Shahid, Ito, James I., Jacobson, Robert M., Johnson, Melissa, Keating, Michael R., Kett, Daniel H., Knapp, Katherine, Kontoyiannis, Dimitrios P., Krcmery, Vladimir C., Larsen, Robert, Laverdiere, Michel, Ljungman, Per, Lortholary, O., Maertens, Johan, Marriott, Debbie, Mattiuzzi, Gloria, McGinnis, Michael R., Morris, Michele, Nucci, Marcio, Odds, Frank C., Pankey, George A., Patterson, Thomas, Pfaller, Mike, Razonable, Raymond R., Reboli, Annette C., Rinaldi, Michael G., Roberts, Glenn D., Tudela, Juan Luis Rodriguez, Rotstein, Coleman, Ruhnke, Markus, Schuster, Mindy, Shoham, Shmuel, Sia, Irene G., Siebel, Nita, Silviera, Fernanda, Singh, Nina, Sobel, Jack, Solomkin, Joseph S., Sorrell, Tania C., Steinbach, William J., Temesgen, Zelalem, Tortorano, AnnaMaria, Vartivarian, Shahe, VerWeij, Paul, Viscoli, Claudio, Viviani, Maria Anna, Walker, Randall C., Wheat, Joseph L., Wiley, Joseph, Williamson, Peter, Wingard, John R., Yu, Victor L., and Zaoutis, Theoklis

Subjects
Clinical trials -- Evaluation, Journalism, Medical -- Evaluation, Health, Health care industry
Published
2006

94. Issues in antifungal stewardship: an opportunity that should not be lost: Table 1

Author

Wattal, Chand, primary, Chakrabarti, Arunaloke, additional, Oberoi, Jaswinder Kaur, additional, Donnelly, J. Peter, additional, Barnes, Rosemary A., additional, Sherwal, B. L., additional, Goel, Neeraj, additional, Saxena, Sonal, additional, Varghese, George M., additional, Soman, Rajeev, additional, Loomba, Poonam, additional, Tarai, Bansidhar, additional, Singhal, Sanjay, additional, Mehta, Naimish, additional, Ramasubramanian, V., additional, Choudhary, Dharma, additional, Mehta, Yatin, additional, Ghosh, Supradip, additional, Muralidhar, Sumathi, additional, and Kaur, Ravinder, additional

Published
2016
Full Text
View/download PDF

97. Risk stratification in febrile neutropenic episodes in adolescent/young adult patients with cancer

Author

Phillips, Robert S., primary, Bhuller, Kaljit, additional, Sung, Lillian, additional, Ammann, Roland A., additional, Tissing, Wim J.E., additional, Lehrnbecher, Thomas, additional, Stewart, Lesley A., additional, Haeusler, Gabrielle M., additional, Bauters, Tiene, additional, Laureys, Geneviève, additional, Spassova, Maria, additional, Klaassen, Robert, additional, Alexander, Sarah, additional, Silva, Pamela, additional, Tordecilla, Juan, additional, Paesmans, Marianne, additional, Donnelly, J. Peter, additional, Simon, Arne, additional, Hann, Ian M., additional, Ranasinghe, Neil, additional, Riley, Richard D., additional, Chisholm, Julia, additional, Yeomanson, Daniel, additional, Sutton, Alex J., additional, Dommett, Rachel, additional, Gupta, Ajay, additional, Castagnola, Elio, additional, Haupt, Ricarrdo, additional, Meidema, Karin, additional, Kuehne, Thomas, additional, Kitanovski, Lidija, additional, Niggli, Felix, additional, Nadal, David, additional, Tezcan, Gulsun, additional, Hakim, Hana, additional, and Stryjewski, Glen, additional

Published
2016
Full Text
View/download PDF

100. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients

Author

Cordonnier, Catherine, primary, Cesaro, Simone, additional, Maschmeyer, Georg, additional, Einsele, Hermann, additional, Donnelly, J. Peter, additional, Alanio, Alexandre, additional, Hauser, Philippe M., additional, Lagrou, Katrien, additional, Melchers, Willem J. G., additional, Helweg-Larsen, Jannik, additional, Matos, Olga, additional, Bretagne, Stéphane, additional, and Maertens, Johan, additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results